Evaluación positiva de medicamentosjunio y julio 2014

  1. P. Sánchez López
  2. M.A. Cabanes Mariscal
  3. A. Tabakov
  4. A. García Luque
Journal:
Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

ISSN: 1887-8571

Year of publication: 2014

Volume: 70

Issue: 4

Pages: 279-281

Type: Article

DOI: 10.4321/S1887-85712014000400007 DIALNET GOOGLE SCHOLAR

More publications in: Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

Abstract

The drugs assessed by the Spanish Agency for Medicines and Health Products made public in June, July and August of 2014, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Bibliographic References

  • Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios.
  • Daclatasvir.
  • Sulkowski, MS, Gardiner, DF, Rodriguez-Torres, M, Reddy, KR, Hassanein, T, Jacobson, I. (2014). Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med.. 370. 211
  • Ficha técnica de Triumeq®.
  • Walmsley, SL, Antela, A, Clumeck, N. (2013). Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med.. 369. 1807-1818
  • Weller, S, Chen, S, Borland, J. Bioequivalence of a Dolutegravir, Abacavir and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food. JAIDS.
  • FDA Summary review.
  • Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios.
  • FDA Medical review.
  • Idelalisib.
Data source: Dialnet